Scilex Holding (SCLXW) Return on Capital Employed (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Return on Capital Employed of 203.13% in Q1 2026, down 4.18% quarter-over-quarter from 211.99% in Q4 2025, and up 15475.0% on a YoY basis from N/an in Q1 2025.
Scilex Holding (SCLXW) Return on Capital Employed (2021 - 2026) Analysis & Trends
Scilex Holding's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 203.13% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 15475.0% year-over-year to 203.13%; the TTM figure through Mar 2026 stood at 203.13% (up 15475.0% YoY), while the FY2025 annual figure was 135.86%, up 8454.0% from the prior year.
- Return on Capital Employed was 203.13% for Q1 2026 at Scilex Holding, down from 211.99% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 211.99% in Q4 2025 to a low of 2940.51% in Q2 2023.
- Historically, Return on Capital Employed has averaged 145.26% across 5 years, with a median of 48.38% in 2025.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 290096 bps in 2023, then surged 299906 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 103.02% in 2022, then surged by 164 bps to 66.12% in 2023, then dropped by 23 bps to 51.18% in 2024, then jumped by 314 bps to 211.99% in 2025, then fell by 4 bps to 203.13% in 2026.
- The last three Return on Capital Employed figures came in at 203.13% (Q1 2026), 211.99% (Q4 2025), and 146.98% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 9.49% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -6.84% |
| 10 | Scilex Holding | - | - | 4.15 Mn | 203.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 203.13% |
| Dec 31, 2025 | 211.99% |
| Sep 30, 2025 | 146.98% |
| Jun 30, 2025 | 43.06% |
| Mar 31, 2025 | 48.38% |
| Dec 31, 2024 | 51.18% |
| Sep 30, 2024 | 40.97% |
| Jun 30, 2024 | 58.55% |
| Mar 31, 2024 | 63.55% |
| Dec 31, 2023 | 66.12% |
| Sep 30, 2023 | 85.41% |
| Jun 30, 2023 | -2,940.51% |
| Mar 31, 2023 | -310.33% |
| Dec 31, 2022 | -103.02% |
| Sep 30, 2022 | -54.61% |
| Jun 30, 2022 | -39.55% |
| Mar 31, 2022 | -40.65% |
| Dec 31, 2021 | 59.11% |
| Sep 30, 2021 | -0.45% |
| Jun 30, 2021 | -0.25% |